Cantor Fitzgerald Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)
I'm PortAI, I can summarize articles.
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on X4 Pharmaceuticals with a $14.00 price target. Shares closed at $3.75, indicating significant upside potential. Kluska, a 5-star analyst, has a 26.9% average return. X4 Pharmaceuticals has a Moderate Buy consensus with a $6.25 price target, suggesting a 66.67% upside. H.C. Wainwright also reiterated a Buy rating with a $5.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments